Results 161 to 170 of about 755,388 (347)

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

open access: yesAdvanced Science, EarlyView.
KG‐FP‐003, a highly potent TEAD‐YAP PROTAC derived from the patented inhibitor is developed. It selectively degrades endogenous TEAD proteins in HiBiT systems without IMiD‐related off‐target effects. Screening across 867 cancer cell lines revealed broad and superior anti‐tumor activity, highlighting its therapeutic potential through targeted TEAD ...
Linhui Cao   +25 more
wiley   +1 more source

Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

open access: yesAdvanced Science, EarlyView.
IDH‐mutant gliomas exhibit sensitivity to PARP inhibitors (PARPi) owing to oncometabolite 2‐HG‐induced DNA repair defects. PARPi treatment induces resistance by upregulating Prickle4, which promotes VEGF‐driven angiogenesis. Combining PARPi veliparib with anti‐angiogenic lenvatinib blocks this pathway, causing tumor regression and prolonged survival in
Ju Yang   +16 more
wiley   +1 more source

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer [PDF]

open access: gold, 2019
Paul Buderath   +6 more
openalex   +1 more source

Ovarian Cancer [PDF]

open access: yesCA: A Cancer Journal for Clinicians, 1974
H R, Barber, E A, Graber, , KwonTH
openaire   +2 more sources

Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer

open access: yesAdvanced Science, EarlyView.
Extracellular vesicle (EV)‐packaged CDC37 are released from TMBhiCTLlo breast cancer cells with high CDC37 expression, and internalized into endo/phagosomes of dendritic cells (DCs). Within these compartments, CDC37 locked HSP90–antigen complex, preventing antigen release into the cytosol.
Ruxin Wang   +10 more
wiley   +1 more source

TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4+ T and NK Cells

open access: yesAdvanced Science, EarlyView.
Impaired anti‐tumor immunity is mediated by TREM2 + macrophages in non‐small cell lung cancer. TREM2 + macrophages prevent anti‐tumor immunity depending on the limitation of CD4 + T and NK cells. TREM2 promotes cholesterol efflux via ABCA1 to limit the production of CX3CL1 in macrophages.
Yunhan Wang   +9 more
wiley   +1 more source

Protein Z: A putative novel biomarker for early detection of ovarian cancer [PDF]

open access: hybrid, 2016
Matthew R. Russell   +15 more
openalex   +1 more source

Trends and racial disparities in aggressive end‐of‐life care for a national sample of women with ovarian cancer [PDF]

open access: bronze, 2021
Megan A. Mullins   +5 more
openalex   +1 more source

Genetic and Functional Evidence Links Germline Biallelic Inactivating Variants in WWOX to Histological Mixed‐Type Thyroid Cancer

open access: yesAdvanced Science, EarlyView.
The role of germline WWOX loss‐of‐function variants in oncogenesis has remained poorly characterized. This study provides the first comprehensive genetic and functional evidence that such variants promote tumorigenesis through the disruption of multiple tumor‐suppressive mechanisms.
Xiaopeng Zhang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy